



TITLE:

# Using CRISPR/Cas9-mediated gene editing to further explore growth and trade-off effects in myostatin-mutated F4 medaka (*Oryzias latipes*)

AUTHOR(S):

Yeh, Ying-Chun; Kinoshita, Masato; Ng, Tze Hann; Chang, Yu-Hsuan; Maekawa, Shun; Chiang, Yi-An; Aoki, Takashi; Wang, Han-Ching

---

CITATION:

Yeh, Ying-Chun ...[et al]. Using CRISPR/Cas9-mediated gene editing to further explore growth and trade-off effects in myostatin-mutated F4 medaka (*Oryzias latipes*). Scientific Reports 2017, 7: 11435.

ISSUE DATE:

2017-09-12

URL:

<http://hdl.handle.net/2433/228152>

RIGHT:

© The Author(s) 2017.; This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

# SCIENTIFIC REPORTS

OPEN

## Using CRISPR/Cas9-mediated gene editing to further explore growth and trade-off effects in myostatin-mutated F4 medaka (*Oryzias latipes*)


Ying-Chun Yeh<sup>1</sup>, Masato Kinoshita<sup>2</sup>, Tze Hann Ng<sup>1</sup>, Yu-Hsuan Chang<sup>1</sup>, Shun Maekawa<sup>1</sup>, Yi-An Chiang<sup>1</sup>, Takashi Aoki<sup>1</sup> & Han-Ching Wang<sup>1,3</sup>

Myostatin (MSTN) suppresses skeletal muscle development and growth in mammals, but its role in fish is less well understood. Here we used CRISPR/Cas9 to mutate the MSTN gene in medaka (*Oryzias latipes*) and evaluate subsequent growth performance. We produced mutant F0 fish that carried different frameshifts in the *O/MSTN* coding sequence and confirmed the heritability of the mutant genotypes to the F1 generation. Two F1 fish with the same heterozygous frame-shifted genomic mutations (a 22 bp insertion in one allele; a 32 bp insertion in the other) were then crossbred to produce subsequent generations (F2–F5). Body length and weight of the *MSTN*<sup>−/−</sup> F4 medaka were significantly higher than in the wild type fish, and muscle fiber density in the inner and outer compartments of the epaxial muscles was decreased, suggesting that MSTN null mutation induces muscle hypertrophy. From 3–4 weeks post hatching (wph), the expression of three major myogenic related factors (MRFs), MyoD, Myf5 and Myogenin, was also significantly upregulated. Some medaka had a spinal deformity, and we also observed a trade-off between growth and immunity in *MSTN*<sup>−/−</sup> F4 medaka. Reproduction was unimpaired in the fast-growth phenotypes.

Myostatin (MSTN) is a member of the transforming growth factor- $\beta$  (TGF- $\beta$ ) superfamily and is a well-known negative regulator of myogenesis in skeletal muscle development<sup>1–5</sup>. After MSTN is produced as a prepropeptide, a proteolytic process releases the C-terminal active domain of MSTN, which then dimerizes to become an activated peptide with biological activity<sup>6–9</sup>. The dimer of the MSTN C-terminal active domain subsequently interacts with membrane receptors and activates Smad2/3 signaling, which in turn initiates a signaling cascade that inhibits the expression of the myogenic regulatory factors (MRFs), including Myf5, myogenin and MyoD<sup>10–12</sup>. Double muscling (i.e. extreme gains in muscle mass) in MSTN-null phenotypes has been characterized in mammals<sup>13–15</sup>. This increase of muscle size in MSTN-null mammals may be caused by hypertrophy (increased muscle fiber size) or hyperplasia (increased number of muscle fibers) or both, and seems to be dependent on the animal species as well as the method used to suppress MSTN<sup>16,17</sup>.

Fast-growing animals are usually preferred in commercial animal culture, and the effect of MSTN on fish first began to be studied nearly twenty years ago<sup>13</sup>. In fish, MSTN proteins are expressed ubiquitously in various tissues and organs, including those in the ingestion system and the reproductive system<sup>18–20</sup>. Most fish species carry two or more copies of MSTN. In teleosts, this has led to a diversification in MSTN functionality and/or mechanisms, and has given rise to various phenotypes in which changes in growth performance and skeletal muscle development can occur via both hyperplasia and/or hypertrophy<sup>21–25</sup>. This diversity means that there is no universal fish research model for MSTN. In the present study, we chose to investigate MSTN function in medaka (*Oryzias*

<sup>1</sup>Institute of Biotechnology, College of Bioscience and Biotechnology, National Cheng Kung University, Tainan, 701, Taiwan. <sup>2</sup>Division of Applied Bioscience, Graduate School of Agriculture, Kyoto University, Kyoto, 606-8502, Japan. <sup>3</sup>Department of Biotechnology and Bioindustry Sciences, National Cheng Kung University, Tainan, Taiwan. Correspondence and requests for materials should be addressed to H.-C.W. (email: [wanghc@mail.ncku.edu.tw](mailto:wanghc@mail.ncku.edu.tw))



**Figure 1.** Our MSTN-sgRNA targets a location upstream of the active C-terminal domain of *O/MSTN*. (A) Schematic representation of the *O/MSTN* gene, which contains three exons, exon 1~3. The active C-terminal domain (black box) is found in exon 3. (B) The MSTN-sgRNA was designed to target a sequence (gray box) upstream of the active C-terminal domain in exon 3. The PAM sequence is shaded.

*latipes*; rice fish). In evolutionary terms, medaka is separated from zebrafish by ~150 MY<sup>26</sup>. It is also unusual- and very convenient for our purposes- in that it has only a single copy of the *MSTN* gene<sup>27</sup>.

Methods that have previously been applied to generate *MSTN*-mutated medaka include transgenesis<sup>24</sup>, TILLING (targeting induced local lesions in the genome) by EMU-mutagenesis<sup>27</sup>, and TALENs (Transcription activator-like effector nucleases)<sup>22</sup>. Here, instead of temporary suppression by RNAi, or disabling *MSTN* by transgenesis or chemical mutagenesis, we used the CRISPR/Cas9 system to create several generations of *MSTN*<sup>-/-</sup> medaka. CRISPR/Cas9 has recently been developed into a powerful endonuclease-based gene editing tool that can be used to mutate specific genes in both eukaryotes and prokaryotes<sup>28-31</sup>, and we anticipated that it would provide several advantages over the currently available alternative platforms. In TALENs, for example, the design and construction of the specific DNA binding protein is more complicated, the overall process is more expensive, and the platform's mutagenic efficiency is lower. Meanwhile, TILLING induces only an in-frame point mutation instead of frame shifts that cause the deletion of an entire functional domain. On the other hand, in the CRISPR/Cas9 platform, the sgRNA can tolerate up to five mismatches, so it is necessary to ensure that no disruptive off-target effects are being induced at other genetic loci. In the first half of this study, after describing how we used the CRISPR/Cas9 platform to produce *MSTN*<sup>-/-</sup> medaka, we confirm that all of the fish carried frame-shifted mutations and that there were no off-target effects. In the second half, we examine the growth performance of the knock-out fish in terms of body weight, body length and the development of muscle fibers. We also monitor the expression of MRFs (myogenic related factors). In addition, since there is often a trade-off between growth and other biological traits, such as immunity<sup>32</sup> and reproduction<sup>33</sup>, we evaluate virus susceptibility by challenging the *MSTN*<sup>-/-</sup> medaka with RGNNV (red spotted grouper nervous necrosis virus) and assess their reproductive performance by monitoring both the number of eggs produced and the number of eggs that were successfully fertilized.


## Results

**Introduction of CRISPR/Cas9 mutations into the *MSTN* gene of medaka.** The medaka genome contains only a single ortholog of the mammalian *MSTN* (*O/MSTN*; Ensembl gene no. ENSORLG00000015057), and we therefore designed our *MSTN*-sgRNA to specifically target this gene. As shown in Fig. 1, the active C terminal domain of *MSTN* is located in exon 3, and the *MSTN*-sgRNA target sequence was located upstream of this active domain on the 5' end of the same exon.

**Breeding the F2-F5 *MSTN*<sup>-/-</sup> medaka progeny and molecular characterization of their CRISPR/Cas9-mediated mutations.** Two F1 fish (F1#9 M and F1#34 F) with the same heterozygous mutation consisting of a 22-bp insertion and a 32-bp insertion (Fig. 2A) were crossed with each other to generate the next generation of *MSTN*<sup>-/-</sup> medaka, F2. Two *MSTN* frame-shifted genotypes were found in 19 tested *MSTN*<sup>-/-</sup> medaka F2 progeny (Fig. 2A). One genotype was a homozygous frame-shift mutation with the same 22-bp insertion, while the other was a heterozygous mutation consisting of the 22-bp insertion and 32-bp insertion. Because the *MSTN* gene was successfully disrupted in all the tested *MSTN*<sup>-/-</sup> medaka F2 progeny, we were able to randomly select pairs of F2 mutants to produce the F3 generation of *MSTN*<sup>-/-</sup> medaka. Screening of the *MSTN*<sup>-/-</sup> F3 medaka confirmed that all 6 of the tested fish carried the same two *MSTN* frame-shifted genotypes as the F2 fish (Fig. 2A). The F4 and F5 generations of *MSTN*<sup>-/-</sup> medaka were obtained in a similar way.

To confirm that there were no off-target effects, we used the web tool CHOPCHOP (<https://chopchop.rc.fas.harvard.edu/index.php>) to predict possible off-targets for the *MSTN* sgRNA sequence used in this study. An off-target site was predicted at chr4:31195001 of the medaka genome (Suppl. Fig. S1A). We designed a PCR primer set to amplify this region, and performed PCR on genomic DNAs extracted from wild type (WT) and *MSTN*<sup>-/-</sup> medaka F5 medaka (Suppl. Fig. S1B). Sequencing showed that the resulting ~430 bp amplicons from WT and *MSTN*<sup>-/-</sup> F5 medaka were identical, suggesting that no off-target effect had occurred on chr4:31195001 (Suppl. Fig. S1C).

Figure 2B further shows the predicted amino acid sequence of the mutated proteins, from which we infer that functional *MSTN* was no longer being expressed in either of these mutants. These results showed that our



**Figure 2.** Genotypes of the two selected *MSTN*<sup>-/-</sup> medaka mutants produced by CRISPR/Cas9-mediated genome editing. **(A)** After sequence analysis confirmed that F1#9 M and F1#34 F both harbored the same two frame-shifted *MSTN* mutations, these two fish were used as a breeding pair. The offspring (F2) of F1#9 M x F1#34 F presented as one of two genotypes, both of which had CRISPR/Cas9-mediated frame-shifted *MSTN* mutation in both alleles. Randomly selected pairs were used to produce subsequent generations (F3-F5), all of which consisted entirely of the same two genotypes. The *MSTN*-sgRNA target sequence is underlined while the gray letters indicate the inserted nucleotides. **(B)** Corresponding amino acid sequences of exon 3 of the WT and two mutant genotypes. The targeted amino acids are shaded and the active C-terminal domain is boxed. The stop codon is represented by “-”.

*MSTN*-sgRNA CRISPR/Cas9 system successfully induced frame-shift mutations in exon 3 of the medaka *MSTN* genome, and that these genomic mutations were successfully transmitted to the subsequent generations. To check whether there was any frame-shift correction of the transcribed *MSTN* mRNA, we designed a PCR primer set to

amplify the C-terminal region of the mRNAs from WT and  $MSTN^{-/-}$  F5 medaka (Suppl. Fig. S2A). The expected 22-bp insertion was detected in the C-terminus of the  $MSTN$  mRNA in each of the  $MSTN^{-/-}$  F5 medaka (Suppl. Fig. S2B). However, in two of the knockout fish ( $MSTN^{-/-}$  #5 and #8), an unexpected 61-bp deletion was sometimes detected even though the genotype of these  $MSTN^{-/-}$  F5 medaka all showed the 22-bp insertion in the C-terminus of the  $MSTN$  gene. We therefore infer that the 61-bp deletion was probably due to an RNA splicing event during  $MSTN$  mRNA maturation. Fortunately, the 61-bp deletion still caused a frame-shifted mutation, suggesting that these fish would still have expressed  $MSTN$  with a non-functional C-terminus (Suppl. Fig. S2C). We therefore conclude that expression of the functional  $MSTN$  protein in the  $MSTN^{-/-}$  F5 medaka was completely disrupted at least in all of the fish that we tested.

**Growth performance and morphology of CRISPR/Cas9-mediated  $MSTN^{-/-}$  F4 medaka.** In general,  $MSTN$  mutations in both mammals and fish result in an increase in growth. We therefore investigated the growth performance of  $MSTN^{-/-}$  F4 medaka from 1 to 8 wph (i.e. from juvenile to adult stages) by using two indicators, the standard length and body weight<sup>27</sup>. As shown in Fig. 3A,B, the growth performance of  $MSTN^{-/-}$  F4 medaka was significantly better than that of WT. At 8 wph, compared with the WT group, relative body length and weight showed an increase of 10.0% and 64.9%, respectively. We also observed an accelerated increase in the body weight of the  $MSTN^{-/-}$  F4 medaka at 6 and 8 wph compared to the corresponding WT controls (Fig. 3B). Although the  $MSTN^{-/-}$  medaka exhibited a longer and wider body trunk than the WT controls, most of them showed relatively normal morphology (Fig. 3C). However, some of the mutants presented an observable deformity. Although the occurrence of this phenotype was not recorded in earlier generations, we observed severe spinal curvature in one of the  $MSTN^{-/-}$  F4 medaka at 6 wph (Fig. 3C) as well as in several of the adult  $MSTN^{-/-}$  F5 medaka (Suppl. Fig. S3A). To check the genotype of the three  $MSTN^{-/-}$  F5 medaka in Suppl. Fig. S3A and two other  $MSTN^{-/-}$  F5 medaka that also presented with the same spinal deformity, we used PCR followed by sequencing of the 450 bp amplicon that includes the  $MSTN$ -sgRNA target site. All of the tested deformed fish showed a homozygous 22 bp insertion at the target site (Suppl. Fig. S3B). (Unless otherwise noted, none of the deformed  $MSTN^{-/-}$  medaka were used in subsequent parts of this study.)

**The expression of MRFs in CRISPR/Cas9-mediated  $MSTN^{-/-}$  F4 medaka.** Because  $MSTN$  is known to activate the Smad2/3 pathway, which in turn leads to the down-regulation of MRFs (myogenic related factors), we next investigated the expression of the Smad2/3-regulated MRFs in  $MSTN^{-/-}$  F4 medaka from 1 to 8 wph. mRNA was extracted from whole WT and  $MSTN^{-/-}$  F4 medaka and subjected to real-time PCR to detect the expression of three major MRFs: Myf5, Myogenin and MyoD<sup>22, 27</sup>. Starting from the post-juvenile stage (4 wph) the expression levels of the three tested MRFs were significantly upregulated in the  $MSTN^{-/-}$  F4 medaka (Fig. 4). Although these results do not demonstrate any direct relationship between  $MSTN$  knockout and Smad, they nevertheless suggest that within 4 weeks of hatching, the Smad 2/3 pathway may be suppressed in  $MSTN^{-/-}$  F4 medaka.

**Effect of CRISPR/Cas9-mediated  $MSTN$  mutation on skeletal muscle development in  $MSTN^{-/-}$  F4 fish.** To monitor skeletal muscle formation in  $MSTN^{-/-}$  F4 fish, we tracked the muscle fiber cellularity and the muscle fiber area using histological analysis. For this experiment, we focused on the inner and outer compartments of the epaxial muscles adjacent to the vertebral column as shown in Fig. 5A,B. Histological examination showed that the muscle fibers in both areas of the  $MSTN^{-/-}$  F4 medaka at 6 wph had a larger cross-sectional area compared to those in WT medaka (Fig. 5C). This observation is reflected in the quantitative data shown in Fig. 5D,E. The cross-sectional area of the average muscle fiber in  $MSTN^{-/-}$  F4 medaka at 6 wph was ~ 3 times bigger than that in WT medaka (Fig. 5D), while the muscle fiber cellularity of both the inner and outer compartments of the epaxial muscles was significantly decreased in  $MSTN^{-/-}$  F4 medaka at 6 wph (Fig. 5E). We further found that, even when there was a significantly different number of muscle fibers in these two compartments, the difference was relatively small (Fig. 5F). Taken together, these data suggest that CRISPR/Cas9-mediated  $MSTN$  mutation in  $MSTN^{-/-}$  F4 fish caused muscle hypertrophy, not hyperplasia.


**Effect of CRISPR/Cas9-mediated  $MSTN$  mutation on the response to virus challenge in  $MSTN^{-/-}$  F4 fish.** There is a well-known trade-off between growth and immunity that has been reported in a range of animals. To assess this effort in medaka,  $MSTN^{-/-}$  F4 fish were challenged with RGNNV by immersion at 1 wph. RGNNV RNA2 expression was used as an indicator of the infection state (Fig. 6A), and the survival rate was also recorded (Fig. 6B). While the survival rates were almost identical in both groups, surprisingly, at 2~3 days post immersion, the expression of RGNNV RNA2 was significantly lower in  $MSTN^{-/-}$  fish. Although the reason for the low virus copy number is unknown, these results suggest that  $MSTN^{-/-}$  fish are sensitive to RGNNV infection even when the copy number is low.

**Effect of CRISPR/Cas9-mediated  $MSTN$  mutation on reproductive performance of  $MSTN^{-/-}$  F4 medaka.** To assess reproductive performance of  $MSTN^{-/-}$  F4 fish, we investigated the egg numbers and fertilization rate of 3~4 pairs of WT and large phenotype/non-deformed  $MSTN^{-/-}$  F4 medaka. During two months of observation, mean egg numbers were 9.1 and 9.7 in the samples of WT and  $MSTN^{-/-}$  F4 medaka, while the fertilization rates were 83% and 86%, respectively (Fig. 7). There was no significant difference in these two reproductive indicators between the WT and  $MSTN^{-/-}$  F4 medaka. We conclude that CRISPR/Cas9-mediated  $MSTN$  mutation does not significantly affect the reproductive performance of  $MSTN^{-/-}$  F4 medaka.

## Discussion


Although the CRISPR/Cas9 system is now widely used to edit target genes in various mammals<sup>22, 23, 34–37</sup> and in zebrafish, it is still only rarely applied to other fish species. Even in medaka, which is another fish model animal, to





**Figure 3.** CRISPR/Cas9-mediated MSTN<sup>-/-</sup> F4 medaka show better growth parameters. (A) Body weight and (B) standard length of wild type (WT) and MSTN<sup>-/-</sup> F4 medaka. Values represent the mean  $\pm$  SD from seven individual samples. Asterisks indicate a significant difference (\* $p$  < 0.05, \*\* $p$  < 0.01 and \*\*\* $p$  < 0.001) between WT and MSTN<sup>-/-</sup> F4 medaka. (C) Morphology of WT and MSTN<sup>-/-</sup> F4 medaka from 1–8 wph. At 6 weeks post-hatching (wph), one of the MSTN<sup>-/-</sup> fish had a spinal deformity (arrow head).


date, there has only been one published study. This recent study was the first to use CRISPR/Cas9 to successfully target the medaka *Dj-1* gene, and it also showed how the resultant mutation in the founder (F0) generation could subsequently be transmitted to the F1 genotypes<sup>38</sup>. Here in the present study, by using the CRISPR/Cas9 system, we not only document the mutated MSTN genotypes of the MSTN<sup>-/-</sup> medaka, we also continued to observe the



**Figure 4.** Gene expression levels of myogenic regulatory factors (MRFs) were increased in MSTN<sup>-/-</sup> F4 medaka. Gene expression in each sample was analyzed by real-time PCR, and the expression levels of the MRFs were normalized against EF-1α mRNA levels. The relative expression levels are shown as fold change compared to the WT group. Each bar represents the mean ± SD from 6–7 individual samples. Asterisks indicate a significant difference (\*p < 0.05, \*\*p < 0.01 and \*\*\*p < 0.001) between WT and MSTN<sup>-/-</sup> medaka.

specific phenotypes through to the F4 and F5 generations. Although other platforms have been used to generate MSTN-mutated fish, to our knowledge, this is the first investigation of the MSTN<sup>-/-</sup> phenotypes produced by the CRISPR/Cas9 system in medaka, and also the first to document the MSTN<sup>-/-</sup> fish for several generations.

Myostatin is a key suppressor of skeletal muscle growth that prevents overdevelopment via the activation of the Smad2/3 pathway to decrease the expression of MRFs, and as expected, in the MSTN<sup>-/-</sup> F4 medaka, three major MRFs were upregulated from 4 weeks post hatching (Fig. 4). Similar results were found for the same three MRFs (MyoD, Myf5 and Myogenin) in TALENs-mediated MSTN<sup>-/-</sup> F2 medaka<sup>22</sup>. Like most MSTN-deficient terrestrial vertebrates and fishes<sup>27,39</sup>, CRISPR/Cas9-mediated MSTN<sup>-/-</sup> medaka also showed a phenotype with better growth performance (Fig. 3), with the acceleration of body weight being proportionally greater than the increase in body length. This body shape, ie the thicker body trunk, is consistent with the phenotypical changes that are seen in transgenic zebrafish that express MSTN antisense RNA<sup>21</sup>, MSTN C315Y mutant medaka produced by the TILLING method<sup>27</sup> and TALENs-mediated MSTN<sup>-/-</sup> medaka<sup>22</sup>. Clearly, all of these results suggest that MSTN deficiency in medaka results in an increase of the growth rate. We further note that this is true even though all the medaka in the TALENs study, both WT and MSTN<sup>-/-</sup>, had a phenotype with a much longer body




**Figure 5.** Histological sections showed evidence of hypertrophic muscle growth in MSTN<sup>-/-</sup> F4 fish. (A) The cross-sections used in this assay were taken from the area shown in the white box. (B) Typical cross-section showing location of the inner and outer compartments<sup>24</sup> of the epaxial muscles adjacent to the vertebral column. (C) H&E staining of the muscle fibers in the indicated compartments of WT and MSTN<sup>-/-</sup> medaka at 2 and 6 wph. (D) Cross-sectional muscle fiber area in the inner and outer compartments (as measured in 10 muscle fibers in 3–4 fish). (E) Muscle fiber density and (F) total numbers of fibers (as measured in 3–4 fish). Values represent the mean ± SD. Asterisks indicate a significant difference (\* $p < 0.05$ , \*\* $p < 0.01$  and \*\*\* $p < 0.001$ ) between WT and MSTN<sup>-/-</sup> medaka.


than the fish used in the present study (eg ~17 mm and ~90 mg at 8 wph for WT in the TALENs study, versus ~10 mm and ~95 mg at 8 wph in the present study).

Muscle mass depends on both the number and size of the muscle fibers, and myostatin appears to be able to act on both<sup>40</sup>. Thus when down-regulation or mutation of MSTN leads to an increased growth rate in most mammals and various fish species, this can be due to either hypertrophy and/or hyperplasia. However, the observed effects are not always consistent even within a species, with different platforms sometimes producing opposite results. For example, mice with a MSTN C313Y missense mutation showed hyperplasia without hypertrophy<sup>16</sup>, while MSTN knockout mice in which the C-terminal region was replaced by a neo cassette had an increased muscle mass that was due to both hypertrophy and hyperplasia<sup>1</sup>. This difference cannot simply be due to incomplete vs complete removal of MSTN functionality by the two respective platforms, because another study reported that transgenic mice that expressed a dominant negative MSTN also showed hypertrophy with hyperplasia<sup>41</sup>. Similarly inconsistent phenotypes have also been found in zebrafish. Zebrafish that expressed a dominant negative MSTN showed hyperplasia without hypertrophy<sup>23</sup>, whereas transgenic zebrafish that expressed MSTN antisense RNA as well as zebrafish in which MSTN had been transiently inactivated by oral administration of MSTN D76A dominant negative recombinant protein both presented with hypertrophy only<sup>21,42</sup>. In the present study, our use of the CRISPR/Cas9 platform to disrupt the bioactive C-terminal domain in exon 3 of the medaka MSTN genes (Figs 1 and 2; Suppl. Fig. S2) would have completely prevented expression of the functional MSTN active domain. As noted above, histological analysis showed that while the mean diameter of the muscle fibers





**Figure 6.** Evidence of increased virus susceptibility of MSTN<sup>-/-</sup> F4 fish. **(A)** Relative expression level of RGNNV RNA2. Since RGNNV is an RNA virus, the amount of RGNNV RNA2 reflects both the number of virus genome copies plus the transcribed virus mRNA. **(B)** The survival rate after immersion challenge with RGNNV. Values represent the mean  $\pm$  SD. Asterisks indicate a significant difference (\* $p < 0.05$ , \*\* $p < 0.01$  and \*\*\* $p < 0.001$ ) between WT and MSTN<sup>-/-</sup> medaka.



**Figure 7.** Egg production and fertilization rate of MSTN<sup>-/-</sup> F4 medaka were not impaired. **(A)** The number of eggs and **(B)** fertilization rates were monitored in females of breeding pairs in WT and MSTN<sup>-/-</sup> F4 medaka at 20 sampling time points during 2 months. Values represent the mean  $\pm$  SD from four pairs of WT and three pairs of large phenotype/non-deformed MSTN<sup>-/-</sup> F4 medaka. Asterisks indicate a significant difference (\* $p < 0.05$ , \*\* $p < 0.01$  and \*\*\* $p < 0.001$ ) between WT and MSTN<sup>-/-</sup> medaka.

in MSTN<sup>-/-</sup> F4 fish was 2.7~2.9 fold larger than in WT (Fig. 5D,E), there was no increase in the number of muscle fibers (Fig. 5F). These results suggest that hypertrophy, not hyperplasia, is the prime mechanism of the additional muscle growth in CRISPR/Cas9-mediated MSTN<sup>-/-</sup> medaka. By contrast, in MSTN C315Y mutant medaka produced by the TILLING method, hypertrophy became significant only at the late adult stage (16 wph) while *mstn*C315Y-induced hyperplasia was seen from the post-juvenile stage onward<sup>27</sup>. Further, in 6-month-old transgenic medaka in which the dominant-negative form of myostatin was overexpressed, the cross-sectional area

of each muscle fiber was actually reduced while the number of fibers increased by a factor of between 1.8–2.4<sup>24</sup>. It will probably not be easy to tease apart the extent to which these results are due to the different platforms. Nevertheless, it seems likely that the presence of endogenous full-length MSTN, even with a TILLING-induced in-frame point mutation, might well lead to different phenotypes than those seen in the off-frame mutations produced by CRISPR/Cas9. To explore these possibilities in detail, more work will need to be done.

Even though most of the CRISPR/Cas9-mediated MSTN<sup>-/-</sup> medaka had an acceptable, relatively normal body shape with a thicker body trunk, some of them (in one batch of 60 eggs, as many as 7 individuals [~12%]) had a spinal deformity (Figs 3C and S3A). This phenotype may have been due to disruption of bone formation, and curiously, we note that MSTN has previously been shown to regulate bone formation in mice: in MSTN knockout mice, total bone cross-sectional area, callus strength and bone mineral density were all increased<sup>43</sup>, and some tendons also become smaller and less flexible<sup>44</sup>. Nevertheless, at this time, the underlying reason for these spinal deformities is still unknown, and in particular the extent to which myostatin may have been involved remains unclear.

It is a fundamental concept that in the course of an organism's life history, it needs to allocate resources between competing physiological processes and attempt to optimize the trade-off between various fitness-enhancing traits. One commonly observed trade-off in fish is growth versus reproduction<sup>45–47</sup>. However in the present study, we found that the reproductive ability of the large phenotype CRISPR/Cas9-mediated MSTN<sup>-/-</sup> medaka was not affected (Fig. 7). Another well-known example is the trade-off between growth and immunity. This kind of trade-off has been studied in poultry<sup>32</sup>, bull calves<sup>48</sup> and sticklebacks<sup>49</sup>. In a previous study, we also found that TALENs-mediated MSTN<sup>-/-</sup> medaka had both a larger phenotype and a compromised immune system<sup>22</sup>. In those fish, there was a down-regulation of immune genes, significantly higher accumulation of virus, and an increased susceptibility to infection by RGNNV. By contrast, when we challenged the CRISPR/Cas9-mediated MSTN<sup>-/-</sup> medaka with the same virus, we found that the virus copy numbers were even lower than in WT (Fig. 6A). The reason for this discrepancy is not clear, but it may be related to the different phenotypes used in the two studies; as noted above, the fish used here were ~40% shorter than those in the TALENs study. Although it is difficult to directly compare results across these two studies, in the present case, by diverting more resources toward growth, the medaka might reduce the availability of these resources to the virus – and thus limit the virus's ability to replicate. Nevertheless, despite the reduced viral load, the mortality rate of the MSTN<sup>-/-</sup> F4 medaka was almost identical to that of the WT (Fig. 6B), suggesting that the immune system in these fish must somehow be impaired and that their susceptibility was greater. This further suggests that while both TALENs and CRISPR/Cas9 systems induce similar muscle growth in MSTN<sup>-/-</sup> fish, at the same time, they also compromise the immune system in different ways. If so, a side-by-side comparison of these two platforms might provide some very useful insights into the underlying mechanisms of immune suppression in MSTN<sup>-/-</sup> medaka.

## Materials and Methods

**Experimental fish and ethics statement.** The medaka (*Oryzias latipes*; Cab strain) used in this study were maintained in transparent plastic rearing containers with a recirculating water system at 28 °C, and a 14/10-h day/night cycle. The fish were fed three times a day with freshly hatched *Artemia* nauplii or commercial feed. All animal experiments in this study were approved by the Laboratory Animal Center of National Cheng Kung University and carried out in accordance with approved guidelines.

**Vectors used for Cas9 nuclease and sgRNA expression.** The two plasmids used for the CRISPR/Cas9 system in this study were obtained from Addgene: pCS2 + hSpCas9 (#51815) and pDR274 (#42250). The pCS2 + hSpCas9 vector is the Cas9 expression vector with a SP6 promoter for Cas9 nuclease expression, while the pDR274 vector has a T7 promoter and was used for sgRNA expression.

**sgRNA design and cloning into the expression vector.** The genomic sequence of medaka *mstn* (*O/MSTN*) was obtained from the medaka genome database at the Ensembl Genome Database Project (Ensembl gene no. ENSORLG00000015057). Design and construction of *O/MSTN*-sgRNA followed a previously described protocol<sup>38,50</sup>. In brief, the selected target site of the *O/MSTN*-sgRNA was a sequence of the form 5'-N<sub>21</sub>GG-3', as recommended in a design guideline published by Ran *et al.*<sup>51</sup>. A pair of the selected *O/MSTN*-sgRNA oligonucleotides in the sense and antisense directions were synthesized by Mission Biotech Co., Ltd. (Taiwan) using an oligonucleotide purification cartridge (OPC). The *O/MSTN* sgRNA was then cloned into the pDR274 vector using the protocols described in Ansai and Kinoshita<sup>38</sup>. The sequences of the *O/MSTN*-sgRNA oligonucleotides are listed in Table 1.

**Synthesis of Cas9 mRNA and *O/MSTN*-sgRNA.** After pCS2 + hSpCas9 was digested by *NotI* treatment, this linearized vector was used as the template for synthesizing capped Cas9 mRNA with a mMessage mMachine SP6 Kit (Life Technologies). The resulting Cas9 mRNA was purified by using a RNeasy Mini Kit (Qiagen). For synthesis of *O/MSTN*-sgRNA, the pDR274 vector containing *O/MSTN*-sgRNA was first digested by *DraI* and then used as the template for sgRNA synthesis using an AmpliScribe T7-Flash Transcription Kit (Epicentre). Ammonium acetate precipitation was used to purify the synthesized *O/MSTN*-sgRNA.

**Embryo microinjection of Cas9 mRNA and *O/MSTN*-sgRNA.** Microinjection of the medaka embryos followed a method described previously by Kinoshita *et al.*<sup>51</sup>. In brief, fertilized eggs were collected within 30 min after spawning and kept in pre-chilled Iwamatsu's balanced salt solution<sup>52</sup> at 4 °C to arrest development. A mixture containing 100 ng/μL of Cas9 mRNA and 25 ng/μL of *O/MSTN*-sgRNA was prepared and injected into the fertilized eggs at the one-cell stage. The injected embryos were then incubated at room temperature in medaka embryo culture medium (0.0001% methylene blue, 0.1% NaCl, 0.3% KCl, 0.004% CaCl<sub>2</sub> · 2H<sub>2</sub>O, 0.016% MgSO<sub>4</sub> · 7H<sub>2</sub>O). After hatching, the larvae were raised to sexual maturity and used as "founder" fish (F0).

	Name	Sequence (5'-3')	Usage	Reference
MSTN-gRNA	O/MSTN-Sense*	TAGGAAGATCTCAGAGGGCCCC	CRISPR/Cas9 target site	This study
	O/MSTN- Antisense*	AAACGGGGCCCTCTGAGATCTT		
Primers	O/MSTN_F2	TCAAGTGCTCACTCAGGCTG	PCR for O/MSTN genotype	ENSORLG00000015057
	O/MSTN_R3	CCACCGTGAGTGGGTAGC	qPCR	Chiang <i>et al.</i> <sup>22</sup>
	O/MyoD-qPCR-F	GCCCCGCTCCAACTG		
	O/MyoD-qPCR-R	CGTCTGACACCTCGGTCCAT		
	O/Myf5-qPCR-F	CGGCGGCTCAAAAAGGT	qPCR	Chiang <i>et al.</i> <sup>22</sup>
	O/Myf5-qPCR-R	GAGGTGCAGCGCTCAGT		
	O/Myogenin-qPCR-F	TTGCCCACCATGGAGCTT	qPCR	Chiang <i>et al.</i> <sup>22</sup>
	O/Myogenin-qPCR-R	AGCGCTGGTCAGGAAAGAAG		
	NNV_RNA2_qPCR_F	5'- GACGCGCTTCAAGCAACTC -3'	qPCR	Chiang <i>et al.</i> <sup>22</sup>
	NNV_RNA2_qPCR_R	5'- CGAACACTCCAGCGACACAGTA -3'		
	O/EF-1 $\alpha$ -qPCR-F	ATTTGCGGGGTTTGCAC	qPCR	Chiang <i>et al.</i> <sup>22</sup>
	O/EF-1 $\alpha$ -qPCR-R	TGGGACTTTTATACGGACTGG		
	Anchor-dTv	GACCACGCGTATCGATGTCGACTTTTTTTTTTTTTTTTV	cDNA synthesis	

**Table 1.** MSTN-sgRNA and PCR primers used in this study. \*Cutting sites are italicized.

**Detection of O/MSTN-CRISPR/Cas9 mediated DNA mutations in F0 founder fish and their offspring.** To observe the genomic DNA mutations induced by Cas9 and O/MSTN-sgRNA in CRISPR/Cas9-mediated MSTN-mutated medaka, a small piece of the caudal fin from individual F0 fish was collected and subjected to genomic DNA analysis as previously described<sup>22,38</sup>. The primer set O/MSTN F2/O/MSTN R3 (Table 1) was used to amplify the region containing the O/MSTN-sgRNA target site in the genomic DNAs extracted from wild type (WT; non-genome-edited Cab strain) and CRISPR/Cas9 treated medaka. The resulting amplicons were then analyzed by heteroduplex mobility assay (HMA) as described previously<sup>53</sup>. The amplicons were also cloned into TA cloning vector (Biolman, Taiwan) and the mutations were sequenced. After the above screening had confirmed the occurrence of CRISPR/Cas9-mediated MSTN mutation in the F0 generation, these founder fish were crossed with each other, and their offspring (F1) were checked for MSTN mutations in the same way.

**Breeding of the F2-F5 MSTN<sup>-/-</sup> generations.** Two of the F1 MSTN<sup>-/-</sup> progeny with the same frame-shifted mutation patterns, F1#9(M) and F1#34(F), were mated to produce the F2 generation. The F2 generation were crossed with each other to produce F3 progeny, and the F4 and F5 progeny were subsequently bred in the same way. The F2 and F3 generations were screened as described above to confirm that the same mutation patterns were successfully inherited. Since F3 was the first generation to produce enough fish for the following assays, only F4 fish were used for this study.

**Collection and assessment of WT and MSTN<sup>-/-</sup> F4 medaka.** WT and F4 eggs were collected daily, and each cohort of larvae (~30) from eggs collected on the same day were maintained in a separate plastic rearing container (3 L) under a 14/10-h day/night cycle at 26°C. For each group of WT and MSTN<sup>-/-</sup> F4 fish, at least 7 tanks were used for growth assessment, quantification of the expression of MRFs (myogenic related factors) genes expression, and histological analysis. At 1, 2, 3, 4, 6 and 8 weeks post-hatching (wph), 7 individual fish were collected for growth assessment and quantification of gene expression. At 2 and 6 weeks post-hatching, another 7 individual fish were collected and fixed for histological analysis using Davidson's fixative solution (33% EtOH, 22% formalin, and 11.5% acetic acid).

**Growth assessment of WT and MSTN<sup>-/-</sup> F4 medaka.** To determine the growth phenotype of WT and CRISPR/Cas9-mediated MSTN<sup>-/-</sup> F4 medaka, the body weight and standard length were measured using a protocol described previously<sup>22</sup>. Briefly, after fish were anesthetized in 0.003% eugenol (Sigma-Aldrich, Inc., MO, USA), the fish were weighed, and after being photographed under a digital microscope, their standard length was measured. The same fish were then immediately transferred to a 1.5 ml tube containing RNA keeper (Protech Technology Enterprise Co., LTD) and subjected to RNA extraction.

**Quantification of the mRNA expression of myogenic related factors (MRFs) in WT and MSTN<sup>-/-</sup> F4 medaka using real-time PCR.** For this experiment, 7 individual WT and MSTN<sup>-/-</sup> F4 medaka were collected at 1, 2, 3, 4, 6 and 8 weeks post-hatching as described above. After RNA extraction, total cDNA was synthesized from each sample using Superscriptase II Reverse Transcriptase (Invitrogen) with Anchor-dTv primer (Table 1). To quantify the relative expression of three major MRFs (MyoD, Myf5 and Myogenin) and the normalization factor EF-1 $\alpha$ , real-time PCR was performed with the specific primer sets listed in Table 1. Data values were calculated by the 2<sup>- $\Delta\Delta C_T$</sup>  method and the expression level of each gene in the WT group was set to 1. Statistically significant differences between WT and MSTN<sup>-/-</sup> F4 medaka were analyzed by Student's t-test.

**Histological analysis of skeletal muscle and muscle fiber density in WT and *O/MSTN-CRISPR/Cas9* mediated *MSTN*<sup>-/-</sup> F4 medaka.** WT and *MSTN*<sup>-/-</sup> medaka were fixed with Davidson's fixative solution and decalcified using EDTA solution (400 mM EDTA, 50 mM Tris-HCl, pH8.3) as described by Chisada *et al.*<sup>27</sup>. Before routine dehydration and paraffin embedding, the fixed fish were pre-embedded in agar-gelatin mixture (1% agar dissolved in 2.5% gelatin solution [300 Bloom])<sup>54</sup>. Paraffin sections (4 μm) were mounted on glass slides, dewaxed and dehydrated, and then stained with hematoxylin and eosin. Muscle formation was measured following the protocol described by Sawatari *et al.*<sup>24</sup> and Chisada *et al.*<sup>27</sup>. Briefly, cross-sections of all specimens were made at the anterior end of the anal fin in the anteroposterior direction. In the inner and outer compartments of the epaxial muscles adjacent to the vertebral column, we used ImageJ software (<http://rsb.info.nih.gov/ij/>) to count the total number of fibers, muscle fiber cellularity (i.e. density of muscle fibers), and the cross-sectional muscle fiber area in 3~5 fish from each group. Statistically significant differences between WT and *MSTN*<sup>-/-</sup> F4 medaka were analyzed by Student's t-test.

**The response to virus challenge in WT and *O/MSTN-CRISPR/Cas9* mediated *MSTN*<sup>-/-</sup> F4 medaka.** Medaka at 1 week after hatching were challenged with RGNNV (red spotted grouper nervous necrosis virus) by bath immersion following the method described by Furusawa *et al.*<sup>55</sup> and Chiang *et al.*<sup>22</sup>. Briefly, fish were challenged RGNNV at 10<sup>9</sup> TCID<sub>50</sub> RGNNV/L for 2 h and then transferred to tanks containing ultraviolet-treated water and 5 μg/ml kanamycin. The survival rate was monitored daily in two groups of 15 fish each. Two more groups of ~20 fish were used to assess the virus load by monitoring the gene expression of the coat protein encoded by RGNNV RNA2 (AY44705). Total RNAs were extracted from three fish from these groups at 1, 2, 3 and 5 days post immersion (dpi). cDNA synthesis was performed by using Superscriptase II Reverse Transcriptase (Invitrogen) and Random hexamer primer. Real-time PCR was then used to measure the expression of RGNNV RNA2 with the primer set NNV\_RNA2\_qPCR\_F/NNV\_RNA2\_qPCR\_R (Table 1). The expression of RGNNV RNA2 was normalized with EF-1α by the 2<sup>-ΔΔCT</sup> method and the expression level of RGNNV RNA2 at 0 dpi in the WT group was set to 1. Statistically significant differences between WT and *MSTN*<sup>-/-</sup> F4 medaka were analyzed by Student's t-test.

**Reproductive performance of WT and *O/MSTN-CRISPR/Cas9* mediated *MSTN*<sup>-/-</sup> F4 medaka.** To determine the reproductive performance of *MSTN*<sup>-/-</sup> F4 medaka, three pairs of WT and *MSTN*<sup>-/-</sup> F4 medaka were selected at random. Eggs from the female of each breeding pair were collected every 2~3 days for 2 months to give a total of 20 samples. For each sample, we recorded both the number of eggs produced and the number of successfully fertilized eggs as observed under a light microscope. Statistically significant differences between WT and *MSTN*<sup>-/-</sup> F4 medaka were analyzed by Student's t-test.

## References

- McPherron, A. C., Lawler, A. M. & Lee, S. J. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. *Nature* **387**, 83–90 (1997).
- Thomas, M. *et al.* 2000. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. *J. Biol. Chem.* **275**, 40235–40243 (2000).
- Schuelke, M. *et al.* Myostatin mutation associated with gross muscle hypertrophy in a child. *N. Engl. J. Med.* **350**, 2682–2688 (2004).
- Mosher, D. S. *et al.* A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. *PLoS Genet.* **3**, e79 (2007).
- Johnson, P. L., McEwan, J. C., Dodds, K. G., Purchas, R. W. & Blair, H. T. Meat quality traits were unaffected by a quantitative trait locus affecting leg composition traits in Texel sheep. *J. Anim. Sci.* **83**, 2729–2735 (2005).
- Thies, R. S. *et al.* GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding. *Growth Factors* **18**, 251–259 (2001).
- Lee, S. J. & McPherron, A. C. Regulation of myostatin activity and muscle growth. *Proc. Natl. Acad. Sci. USA.* **98**, 9306–9311 (2001).
- Zimmers, T. A. *et al.* Induction of cachexia in mice by systemically administered myostatin. *Science* **296**, 1486–1488 (2002).
- Hill, J. J., Qiu, Y., Hewick, R. M. & Wolfman, N. M. Regulation of myostatin *in vivo* by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains. *Mol. Endocrinol.* **17**, 1144–1154 (2003).
- Montarras, D., Lindon, C., Pinset, C., Domeyne, P. Cultured myf5 null and myoD null muscle precursor cells display distinct growth defects. *Biol. Cell* **92**, 565–572 (2000).
- Langley, B. *et al.* Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. *J. Biol. Chem.* **277**, 49831–49840 (2002).
- Watts, R., McAinch, A. J., Dixon, J. B., O'Brien, P. E. & Cameron-Smith, D. Increased Smad signaling and reduced MRF expression in skeletal muscle from obese subjects. *Obesity (Silver Spring)* **21**, 525–528 (2013).
- McPherron, A. C. & Lee, S. J. Double muscling in cattle due to mutations in the myostatin gene. *Proc. Natl. Acad. Sci. USA.* **94**, 12457–12461 (1997).
- Grobet, L. *et al.* A deletion in the bovine myostatin gene causes the double-muscling phenotype in cattle. *Nat. Genet.* **17**, 71–74 (1997).
- Qian, L. *et al.* Targeted mutations in myostatin by zinc-finger nucleases result in double-muscling phenotype in Meishan pigs. *Sci. Rep.* **5**, 14435 (2015).
- Nishi, M. *et al.* A missense mutant myostatin causes hyperplasia without hypertrophy in the mouse muscle. *Biochem. Biophys. Res. Commun.* **293**, 247–251 (2002).
- Acosta, J., Carpio, Y., Borroto, I., González, O. & Estrada, M. P. Myostatin gene silenced by RNAi show a zebrafish giant phenotype. *J. Biotechnol.* **119**, 324–331 (2005).
- Rodgers, B. D., Weber, G. M., Sullivan, C. V. & Levine, M. A. Isolation and characterization of myostatin complementary deoxyribonucleic acid clones from two commercially important fish: *Oreochromis mossambicus* and *Morone chrysops*. *Endocrinology* **142**, 1412–1418 (2001).
- Roberts, S. B. & Goetz, F. W. Differential skeletal muscle expression of myostatin across teleost species, and the isolation of multiple myostatin isoforms. *FEBS Letts.* **491**, 212–216 (2001).
- Maccatrozzo, L., Bargelloni, L., Radaelli, G., Mascarello, F. & Patarnello, T. Characterization of the myostatin gene in the gilthead seabream (*Sparus aurata*): sequence, genomic structure, and expression pattern. *Mar. Biotechnol. (NY)* **3**, 224–230 (2001).



21. Lee, C. Y. *et al.* Suppression of myostatin with vector-based RNA interference causes a double-muscle effect in transgenic zebrafish. *Biochem. Biophys. Res. Commun.* **387**, 766–771 (2009).
22. Chiang, Y. A. *et al.* TALENs-mediated gene disruption of myostatin produces a larger phenotype of medaka with an apparently compromised immune system. *Fish Shellfish Immunol.* **48**, 212–220 (2016).
23. Xu, C., Wu, G., Zohar, Y. & Du, S. J. Analysis of myostatin gene structure, expression and function in zebrafish. *J. Exp. Biol.* **206**, 4067–4079 (2003).
24. Sawatari, E. *et al.* Overexpression of the dominant-negative form of myostatin results in doubling of muscle-fiber number in transgenic medaka (*Oryzias latipes*). *Comp. Biochem. Physiol. A. Mol. Integr. Physiol.* **155**, 183–189 (2010).
25. Terova, G., Rimoldi, S., Bernardini, G. & Saroglia, M. Inhibition of myostatin gene expression in skeletal muscle of fish by *in vivo* electrically mediated dsRNA and shRNAi delivery. *Mol. Biotechnol.* **54**, 673–684 (2013).
26. Kirchmaier, S., Naruse, K., Wittbrodt, J. & Loosli, F. The genomic and genetic toolbox of the teleost medaka (*Oryzias latipes*). *Genetics* **199**, 905–918 (2015).
27. Chisada, S. *et al.* Myostatin-deficient medaka exhibit a double-muscling phenotype with hyperplasia and hypertrophy, which occur sequentially during post-hatch development. *Dev. Biol.* **359**, 82–94 (2011).
28. Makarova, K. S., Aravind, L., Wolf, Y. I. & Koonin, E. V. Unification of Cas protein families and a simple scenario for the origin and evolution of CRISPR-Cas systems. *Biol. Direct.* **66**, 38 (2011).
29. Cong, L. *et al.* Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**, 819–823 (2013).
30. Chylinski, K., Le Rhun, A. & Charpentier, E. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems. *RNA Biol.* **10**, 726–737 (2013).
31. Ran, F. A. *et al.* Genome engineering using the CRISPR-Cas9 system. *Nat. Protoc.* **8**, 2281–2308 (2013).
32. van der Most, P. J., de Jong, B., Parmentier, H. K. & Verhulst, S. Trade-off between growth and immune function: a meta-analysis of selection experiments. *Functional Ecology* **25**, 74–80 (2011).
33. Dunlop, E. S., Heino, M. & Dieckmann, U. Eco-genetic modeling of contemporary life-history evolution. *Ecol. Appl.* **19**, 1815–1834 (2009).
34. Zhou, F., Sun, R., Chen, H., Fei, J. & Lu, D. Myostatin gene mutated mice induced with tale nucleases. *Anim. Biotechnol.* **26**, 169–179 (2015).
35. Proudfoot, C. *et al.* Genome edited sheep and cattle. *Transgenic Res.* **24**, 147–153 (2015).
36. Crispo, M. *et al.* Efficient generation of myostatin knock-out sheep using CRISPR/Cas9 technology and microinjection into zygotes. *Plos one* **10**, e0136690 (2015).
37. Oishi, I., Yoshii, K., Miyahara, D., Kagami, H. & Tagami, T. Targeted mutagenesis in chicken using CRISPR/Cas9 system. *Sci. Rep.* **6**, 23980 (2016).
38. Ansai, S. & Kinoshita, M. Targeted mutagenesis using CRISPR/Cas system in medaka. *Biol. Open* **3**, 362–371 (2014).
39. Du, W. *et al.* Effect of MSTN propeptide protein on the growth and development of Altay lamb muscle. *Genet. Mol. Res.* **15**, doi:10.4238/gmr.15027778 (2016).
40. Carnac, G., Vernus, B. & Bonniou, A. Myostatin in the pathophysiology of skeletal muscle. *Curr Genomics* **8**, 415–422 (2007).
41. Zhu, X., Hadhazy, M., Wehling, M., Tidball, J. G. & McNally, E. M. Dominant negative myostatin produces hypertrophy without hyperplasia in muscle. *FEBS Lett.* **474**, 71–75 (2000).
42. Fuentes, E. N. *et al.* Transient inactivation of myostatin induces muscle hypertrophy and overcompensatory growth in zebrafish via inactivation of the SMAD signaling pathway. *J. Biotechnol.* **168**, 295–302 (2013).
43. Elkasrawy, M. N. & Hamrick, M. W. Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. *J. Musculoskelet. Neuronal Interact.* **10**, 56–63 (2010).
44. Mendias, C. L., Bakhurin, K. I. & Faulkner, J. A. Tendons of myostatin-deficient mice are small, brittle, and hypocellular. *Proc. Natl. Acad. Sci. USA.* **105**, 388–393 (2008).
45. Roff, D. A. An allocation model of growth and reproduction in fish. *Can. J. Fish Aquat. Sci.* **40**, 1395–1404 (1983).
46. van Rooij, J. M., Bruggemann, J. H., Videler, J. J. & Breeman, A. M. Plastic growth of the herbivorous reef fish *Sparisoma viride*: field evidence for a trade-off between growth and reproduction. *Mar. Ecol. Prog. Ser.* **122**, 93–105 (1995).
47. Folkvord, A. *et al.* Trade-offs between growth and reproduction in wild Atlantic cod. *Can. J. Fish Aquat. Sci.* **71**, 1106–1112 (2014).
48. Foote, M. R., Nonnecke, B. J., Beitz, D. C. & Waters, W. R. High growth rate fails to enhance adaptive immune responses of neonatal calves and is associated with reduced lymphocyte viability. *J. Dairy Sci.* **90**, 404–417 (2007).
49. Barber, I. Parasites grow larger in faster growing fish hosts. *Int. J. Parasitol.* **35**, 137–143 (2005).
50. Chang, N. *et al.* Genome editing with RNA-guided Cas9 nuclease in zebrafish embryos. *Cell Res.* **23**, 465–472 (2013).
51. Kinoshita, M., Kani, S., Ozato, K. & Wakamatsu, Y. Activity of the medaka translation elongation factor 1 $\alpha$ -A promoter examined using the GFP gene as a reporter. *Dev. Growth Differ.* **42**, 469–478 (2000).
52. Iwamatsu, T. A new technique for dechoriation and observations on the development of naked eggs in *Oryzias latipes*. *J. Exp. Zool.* **228**, 83–89 (1983).
53. Ansai, S. *et al.* Design, evaluation, and screening methods for efficient targeted mutagenesis with transcription activator-like effector nucleases in medaka. *Dev. Growth Differ.* **56**, 98–107 (2014).
54. Jones, M. V. & Calabresi, P. A. Agar-gelatin for embedding tissues prior to paraffin processing. *Biotechniques* **42**, 569–570 (2007).
55. Furusawa, R., Okinaka, Y. & Nakai, T. Betanodavirus infection in the freshwater model fish medaka (*Oryzias latipes*). *J. Gen. Virol.* **87**, 2333–2339 (2006).

## Acknowledgements

This study was supported financially by the Ministry of Science and Technology (MOST 105-2633-B-006-004). We thank Mr. Paul Barlow, National Cheng Kung University, for his helpful criticism of the manuscript.

## Author Contributions

Y.-C.Y., M.K., Y.-A.C., T.A. and H.-C.W. designed research; Y.-C.Y., M.K., T.H.N., Y.-H.C., S.M. and Y.-A.C. performed research; Y.-C.Y., M.K., T.H.N., Y.-H.C., S.M., Y.-A.C., T.A. and H.-C.W. analyzed data; and Y.-C.Y. and H.-C.W. wrote the paper. All authors read and approved the final manuscript.

## Additional Information

**Supplementary information** accompanies this paper at doi:10.1038/s41598-017-09966-9

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017